^{Genomics and Molecular Biology}

Michael Bergel is currently an Associate Professor at Texas Woman’s University (TWU), the largest university primarily for women in the United States. His lab has recently submitted a provisional patent application: U S Provisional Patent Application No. 62/567,089 entitled “Use of histone acetyltransferase inhibitor amidoximes as anti-proliferative agents”, fi led October 2, 2017. During his Postdoctoral training at the NIH, NCI with Dr. M Bustin, he specialized in the fi eld of chromatin. Specifi cally, he studied the HMGN1/2 proteins and their acetylation by the histone acetyltransferases p300 and PCAF. He also demonstrated that HMGNs are involved in regulation of core histone posttranslational modifi cations. He obtained his Master’s and PhD from the Hebrew University of Jerusalem in the fi eld of Cancer Biology, mentored by Dr. Jacob Hochman. His research interest includes chromatin, cancer biology, DNA repair and cellular UV response.